SLU-PP-332 250mcg 100pcs Oral steroids tablets

Description

SLU-PP-332 Oral ERR Pan-Agonist Exercise Mimetic Research

Molecular Data

• CAS Number: 2828438-23-3
• Molecular Formula: C20H15F3N2O2S
• Molecular Weight: 404.41 g/mol
• Purity: >99.0% via HPLC-UV and MS
• Appearance: Fine white to off-white crystalline powder

Mode of Action

The biochemical activity of SLU-PP-332 is defined by its ability to act as a potent, high-affinity ligand for the orphan nuclear receptors of the ERR family. The primary mechanism involves the molecule enters the cell and agonizes the ligand-binding domains of ERRα, ERRβ, and ERRγ simultaneously. This defines the first semantic triple: [SLU-PP-332 agonizes Estrogen-Related Receptors]. Secondly, this activation triggers the recruitment of co-activators like PGC-1α, which upregulates the transcription of genes involved in mitochondrial oxidative phosphorylation. This establishes the second triple: [ERR activation upregulates PGC-1alpha expression]. Furthermore, the resulting genomic shift enhances the capacity for fatty acid oxidation and shifts the myofibrillar energy preference toward lipid substrate utilization. This forms the third triple: [Metabolic remodeling enhances fatty acid oxidation]. Quantitatively, SLU-PP-332 possesses a systemic half-life of approximately 3.2 hours ($t_{1/2}=3.2pm0.6$h). In comparative studies, SLU-PP-332 is distinguished from SR9009 or GW-501516 by its specific targeting of the ERR axis rather than the Rev-Erb or PPARδ pathways, providing a more direct model for studying mitochondrial density.

Product Profile

SLU-PP-332 is a first-in-class synthetic pan-agonist of the Estrogen-Related Receptors (ERRα, β, and γ), functioning as a potent exercise mimetic. [SLU-PP-332 agonizes Estrogen-Related Receptors]. This signaling molecule serves as a primary research benchmark for investigating the genomic regulation of oxidative metabolism and the molecular triggers of skeletal muscle remodeling without physical exertion.

Experimental Outcomes

• Enhanced Aerobic Endurance: Users in research models report significant increases in running distance and time to exhaustion during mechanical loading.
• Adipose Tissue Mobilization: Experimental findings suggest a marked reduction in fat mass through optimized mitochondrial fatty acid flux.
• Improved Insulin Sensitivity: Based on community feedback, research shows stabilized glucose markers and enhanced peripheral glucose disposal.
• Myofibrillar Preservation: Cross-study analysis suggests potential resistance to muscle atrophy even during periods of metabolic or physical inactivity.
• Increased Basal Metabolic Rate: Research models have observed elevated energy expenditure driven by the upregulation of mitochondrial biogenesis.

In Brief:
SLU-PP-332 Oral represents a premier research tool for investigating the targeted genomic control of metabolism and the molecular pathways of mitochondrial biogenesis.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.